Anti-inflammatory effects of systemic anti-tumour necrosis factor [alpha] treatment in human/murine SCID arthritis
OBJECTIVES To evaluate in vivo the contribution of tumour necrosis factor α (TNFα) to the chimeric transfer model of human rheumatoid arthritis synovial membrane into SCID mice (hu/mu SCID arthritis), systemic anti-TNFα treatment was performed and the clinical, serological, and histopathological eff...
Gespeichert in:
Veröffentlicht in: | Annals of the rheumatic diseases 1999-07, Vol.58 (7), p.428 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 7 |
container_start_page | 428 |
container_title | Annals of the rheumatic diseases |
container_volume | 58 |
creator | Schädlich, Hiltrud Ermann, Jörg Biskop, Maria Falk, Werner Sperling, Frauke Jungel, Astrid Lehmann, Jörg Emmrich, Frank Sack, Ulrich |
description | OBJECTIVES To evaluate in vivo the contribution of tumour necrosis factor α (TNFα) to the chimeric transfer model of human rheumatoid arthritis synovial membrane into SCID mice (hu/mu SCID arthritis), systemic anti-TNFα treatment was performed and the clinical, serological, and histopathological effects of this treatment assessed. METHODS Animals were treated with the rat-antimouse TNFα monoclonal antibody V1q, starting on day 1 after hu/mu engraftment, twice weekly for 12 weeks. Joint swelling, serum concentrations of human and murine interleukin 6 (IL6), and serum amyloid P (SAP) were measured. Histopathological and immunohistochemical analyses of the joints were also performed at the end of treatment. RESULTS Neutralisation of murine TNFα induced the following effects: (a) reduction of extent and duration of the acute arthritis phase, with significant reduction of joint swelling at two weeks; (b) decrease of murine SAP concentrations after the first antibody administration; and (c) increase of murine IL6 in the serum. At the end of treatment, there was a significant reduction of the inflammatory infiltration in the engrafted joints. Because of the mild degree of joint erosion, no treatment effects could be demonstrated on the destructive process. CONCLUSION In the lymphocyte independent hu/mu SCID arthritis, anti-TNFα treatment reduces local and systemic signs of inflammation. |
doi_str_mv | 10.1136/ard.58.7.428 |
format | Article |
fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1778062798</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008310741</sourcerecordid><originalsourceid>FETCH-proquest_journals_17780627983</originalsourceid><addsrcrecordid>eNqNjc1KxDAUhYMoWH92PsAF1-0kbU0ySxmVca27YRguNaEZmmTMvV3M21vBB3B1-Djf4QjxoGSjVKdXWL6aJ9uYpm_thahUr23dSi0vRSWl7Op-rc21uCE6LiitspUoz4lDHZKfMEbkXM7gvHcDE2QPdCZ2MQyAvxbPMc8FkhtKpkDgcVgGsMPpNOIeuDjk6BJDSDDOEdMqziUkBx-b9xfAwmMJHOhOXHmcyN3_5a14fHv93GzrU8nfsyM-HJebtFQHZYyVujVr2_3P-gHddVJY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1778062798</pqid></control><display><type>article</type><title>Anti-inflammatory effects of systemic anti-tumour necrosis factor [alpha] treatment in human/murine SCID arthritis</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Schädlich, Hiltrud ; Ermann, Jörg ; Biskop, Maria ; Falk, Werner ; Sperling, Frauke ; Jungel, Astrid ; Lehmann, Jörg ; Emmrich, Frank ; Sack, Ulrich</creator><creatorcontrib>Schädlich, Hiltrud ; Ermann, Jörg ; Biskop, Maria ; Falk, Werner ; Sperling, Frauke ; Jungel, Astrid ; Lehmann, Jörg ; Emmrich, Frank ; Sack, Ulrich</creatorcontrib><description>OBJECTIVES To evaluate in vivo the contribution of tumour necrosis factor α (TNFα) to the chimeric transfer model of human rheumatoid arthritis synovial membrane into SCID mice (hu/mu SCID arthritis), systemic anti-TNFα treatment was performed and the clinical, serological, and histopathological effects of this treatment assessed. METHODS Animals were treated with the rat-antimouse TNFα monoclonal antibody V1q, starting on day 1 after hu/mu engraftment, twice weekly for 12 weeks. Joint swelling, serum concentrations of human and murine interleukin 6 (IL6), and serum amyloid P (SAP) were measured. Histopathological and immunohistochemical analyses of the joints were also performed at the end of treatment. RESULTS Neutralisation of murine TNFα induced the following effects: (a) reduction of extent and duration of the acute arthritis phase, with significant reduction of joint swelling at two weeks; (b) decrease of murine SAP concentrations after the first antibody administration; and (c) increase of murine IL6 in the serum. At the end of treatment, there was a significant reduction of the inflammatory infiltration in the engrafted joints. Because of the mild degree of joint erosion, no treatment effects could be demonstrated on the destructive process. CONCLUSION In the lymphocyte independent hu/mu SCID arthritis, anti-TNFα treatment reduces local and systemic signs of inflammation.</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/ard.58.7.428</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Animals ; Antigens ; Arthritis ; Cytokines ; Experiments ; Gangrene ; Immunoglobulins ; Immunology ; Inflammation ; Joint surgery ; Knee ; Medical research ; Medicine ; Proteins ; Studies ; Tumor necrosis factor-TNF</subject><ispartof>Annals of the rheumatic diseases, 1999-07, Vol.58 (7), p.428</ispartof><rights>Copyright: 1999 Annals of the Rheumatic Diseases</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Schädlich, Hiltrud</creatorcontrib><creatorcontrib>Ermann, Jörg</creatorcontrib><creatorcontrib>Biskop, Maria</creatorcontrib><creatorcontrib>Falk, Werner</creatorcontrib><creatorcontrib>Sperling, Frauke</creatorcontrib><creatorcontrib>Jungel, Astrid</creatorcontrib><creatorcontrib>Lehmann, Jörg</creatorcontrib><creatorcontrib>Emmrich, Frank</creatorcontrib><creatorcontrib>Sack, Ulrich</creatorcontrib><title>Anti-inflammatory effects of systemic anti-tumour necrosis factor [alpha] treatment in human/murine SCID arthritis</title><title>Annals of the rheumatic diseases</title><description>OBJECTIVES To evaluate in vivo the contribution of tumour necrosis factor α (TNFα) to the chimeric transfer model of human rheumatoid arthritis synovial membrane into SCID mice (hu/mu SCID arthritis), systemic anti-TNFα treatment was performed and the clinical, serological, and histopathological effects of this treatment assessed. METHODS Animals were treated with the rat-antimouse TNFα monoclonal antibody V1q, starting on day 1 after hu/mu engraftment, twice weekly for 12 weeks. Joint swelling, serum concentrations of human and murine interleukin 6 (IL6), and serum amyloid P (SAP) were measured. Histopathological and immunohistochemical analyses of the joints were also performed at the end of treatment. RESULTS Neutralisation of murine TNFα induced the following effects: (a) reduction of extent and duration of the acute arthritis phase, with significant reduction of joint swelling at two weeks; (b) decrease of murine SAP concentrations after the first antibody administration; and (c) increase of murine IL6 in the serum. At the end of treatment, there was a significant reduction of the inflammatory infiltration in the engrafted joints. Because of the mild degree of joint erosion, no treatment effects could be demonstrated on the destructive process. CONCLUSION In the lymphocyte independent hu/mu SCID arthritis, anti-TNFα treatment reduces local and systemic signs of inflammation.</description><subject>Animals</subject><subject>Antigens</subject><subject>Arthritis</subject><subject>Cytokines</subject><subject>Experiments</subject><subject>Gangrene</subject><subject>Immunoglobulins</subject><subject>Immunology</subject><subject>Inflammation</subject><subject>Joint surgery</subject><subject>Knee</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Proteins</subject><subject>Studies</subject><subject>Tumor necrosis factor-TNF</subject><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNjc1KxDAUhYMoWH92PsAF1-0kbU0ySxmVca27YRguNaEZmmTMvV3M21vBB3B1-Djf4QjxoGSjVKdXWL6aJ9uYpm_thahUr23dSi0vRSWl7Op-rc21uCE6LiitspUoz4lDHZKfMEbkXM7gvHcDE2QPdCZ2MQyAvxbPMc8FkhtKpkDgcVgGsMPpNOIeuDjk6BJDSDDOEdMqziUkBx-b9xfAwmMJHOhOXHmcyN3_5a14fHv93GzrU8nfsyM-HJebtFQHZYyVujVr2_3P-gHddVJY</recordid><startdate>19990701</startdate><enddate>19990701</enddate><creator>Schädlich, Hiltrud</creator><creator>Ermann, Jörg</creator><creator>Biskop, Maria</creator><creator>Falk, Werner</creator><creator>Sperling, Frauke</creator><creator>Jungel, Astrid</creator><creator>Lehmann, Jörg</creator><creator>Emmrich, Frank</creator><creator>Sack, Ulrich</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>19990701</creationdate><title>Anti-inflammatory effects of systemic anti-tumour necrosis factor [alpha] treatment in human/murine SCID arthritis</title><author>Schädlich, Hiltrud ; Ermann, Jörg ; Biskop, Maria ; Falk, Werner ; Sperling, Frauke ; Jungel, Astrid ; Lehmann, Jörg ; Emmrich, Frank ; Sack, Ulrich</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_17780627983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Animals</topic><topic>Antigens</topic><topic>Arthritis</topic><topic>Cytokines</topic><topic>Experiments</topic><topic>Gangrene</topic><topic>Immunoglobulins</topic><topic>Immunology</topic><topic>Inflammation</topic><topic>Joint surgery</topic><topic>Knee</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Proteins</topic><topic>Studies</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schädlich, Hiltrud</creatorcontrib><creatorcontrib>Ermann, Jörg</creatorcontrib><creatorcontrib>Biskop, Maria</creatorcontrib><creatorcontrib>Falk, Werner</creatorcontrib><creatorcontrib>Sperling, Frauke</creatorcontrib><creatorcontrib>Jungel, Astrid</creatorcontrib><creatorcontrib>Lehmann, Jörg</creatorcontrib><creatorcontrib>Emmrich, Frank</creatorcontrib><creatorcontrib>Sack, Ulrich</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schädlich, Hiltrud</au><au>Ermann, Jörg</au><au>Biskop, Maria</au><au>Falk, Werner</au><au>Sperling, Frauke</au><au>Jungel, Astrid</au><au>Lehmann, Jörg</au><au>Emmrich, Frank</au><au>Sack, Ulrich</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-inflammatory effects of systemic anti-tumour necrosis factor [alpha] treatment in human/murine SCID arthritis</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>1999-07-01</date><risdate>1999</risdate><volume>58</volume><issue>7</issue><spage>428</spage><pages>428-</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>OBJECTIVES To evaluate in vivo the contribution of tumour necrosis factor α (TNFα) to the chimeric transfer model of human rheumatoid arthritis synovial membrane into SCID mice (hu/mu SCID arthritis), systemic anti-TNFα treatment was performed and the clinical, serological, and histopathological effects of this treatment assessed. METHODS Animals were treated with the rat-antimouse TNFα monoclonal antibody V1q, starting on day 1 after hu/mu engraftment, twice weekly for 12 weeks. Joint swelling, serum concentrations of human and murine interleukin 6 (IL6), and serum amyloid P (SAP) were measured. Histopathological and immunohistochemical analyses of the joints were also performed at the end of treatment. RESULTS Neutralisation of murine TNFα induced the following effects: (a) reduction of extent and duration of the acute arthritis phase, with significant reduction of joint swelling at two weeks; (b) decrease of murine SAP concentrations after the first antibody administration; and (c) increase of murine IL6 in the serum. At the end of treatment, there was a significant reduction of the inflammatory infiltration in the engrafted joints. Because of the mild degree of joint erosion, no treatment effects could be demonstrated on the destructive process. CONCLUSION In the lymphocyte independent hu/mu SCID arthritis, anti-TNFα treatment reduces local and systemic signs of inflammation.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ard.58.7.428</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-4967 |
ispartof | Annals of the rheumatic diseases, 1999-07, Vol.58 (7), p.428 |
issn | 0003-4967 1468-2060 |
language | eng |
recordid | cdi_proquest_journals_1778062798 |
source | EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
subjects | Animals Antigens Arthritis Cytokines Experiments Gangrene Immunoglobulins Immunology Inflammation Joint surgery Knee Medical research Medicine Proteins Studies Tumor necrosis factor-TNF |
title | Anti-inflammatory effects of systemic anti-tumour necrosis factor [alpha] treatment in human/murine SCID arthritis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T17%3A49%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-inflammatory%20effects%20of%20systemic%20anti-tumour%20necrosis%20factor%20%5Balpha%5D%20treatment%20in%20human/murine%20SCID%20arthritis&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Sch%C3%A4dlich,%20Hiltrud&rft.date=1999-07-01&rft.volume=58&rft.issue=7&rft.spage=428&rft.pages=428-&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/ard.58.7.428&rft_dat=%3Cproquest%3E4008310741%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1778062798&rft_id=info:pmid/&rfr_iscdi=true |